Jul 16 2013

george

Does Riva Affect Thrombophilia Tests?

A message from Crystal Azevedo, Eastern Maine Healthcare System: Hello George, I was wondering if you or your colleagues are familiar with the interfering effects of rivaroxaban on tests for thrombophilia? I am testing a sample of plasma where the prescribed dose is 15 mg twice per day, and most of the test results are suspect. Thanks […]

read more

Comments (1)

Anticoagulant Therapy

Jul 3 2013

george

POC Screening for Coumadin Effect

From John McClure: We have been approached by our neurology and ER services to establish point of care prothrombin time/international normalized ratio (PT/INR) testing to assess for Coumadin effect prior to initiating thrombolytic therapy in stroke patients. One of our point of care (POC) coordinators has pointed out that the devices are FDA approved for monitoring […]

read more

Comments (0)

Anticoagulant Therapy

Jul 2 2013

george

In-house Dilute TT

Dear George, I greatly appreciate your website and congratulate you on have such a informative and open educational forum. I was wondering if it was possible to add “in-house dilute thrombin time” to the current Quick Question list? Thank you for your consideration. Sincerely, Glen Holloway. Hello, Glen, and thank you for your suggestion. I will […]

read more

Comments (2)

Anticoagulant Therapy

Jun 30 2013

george

Transient Recurrent FVII Deficiency?

Another from Linda Stang, Alberta Health Service: We have a patient with ‘transient, recurrent’ factor VII deficiency that I suspect is drug related. When FVII is low, protein C and factor X are normal. Patient has been as high as 1.57 u/mL and as low as 0.08 u/mL. Do you or any of your participants have […]

read more

Comments (0)

Anticoagulant Therapy

Jun 14 2013

george

Pradaxa Measurement: An Oxymoron?

George sent this message to Dr. David Alter, Spectrum Health System, Grand Rapids, Michigan (once named Butterworth Hospital), regarding a question he posted on MEDLAB-L on Monday, June 10, asking, “Isn’t monitoring Pradaxa an oxymoron?”: “Hi, Dr. Alter. I subscribe to MEDLAB-L and just saw your post regarding Pradaxa measurement. May I post your question and some discussion […]

read more

Comments (1)

Anticoagulant Therapy

Jun 11 2013

george

What is an RUO/IUO?

We’ve had several posts about measuring the new oral anticoagulants, the most pressing concern for coagulation laboratories around the world as they are confronted with the need to determine the presence and levels of dabigatran, rivaroxaban, apixaban, and soon, edoxaban. Though pharmaceutical distributors reassure us there is no need for monitoring, we are confronted with […]

read more

Comments (1)

Anticoagulant Therapy

Jun 11 2013

george

Rx Level for Dabi?

Dave McGlasson, hemostasis researcher at Wilford Hall USAF Medical Center in San Antonio, is engaged in a large-scale dabigatran measurement project. He reports that a prominent Midwestern medical center uses 45–95 ng/mL as their therapeutic range, using the plasma-diluted thrombin time (DTT, Hemoclot® direct thrombin inhibitor). In the article in Europace (2013) 15, 625–51 (posted May 9, 2013 […]

read more

Comments (0)

Anticoagulant Therapy

Jun 5 2013

george

Measuring Dabi and Riva

From Kim Kinney at IU Health (formerly Clarian): Our coag lab is being asked by our heme/onc docs to have an assay for both Rivaroxaban and Dabigatran. I thought maybe you could poll your readers to see who is doing what type of assay if any! As always, thanks for your help. Hi, Kim, it is good to hear […]

read more

Comments (2)

Anticoagulant Therapy

May 9 2013

george

ARISTOTLE Analysis: Apixaban Superior to Warfarin

A May 7, 2013 report from the ARISTOTLE trial was highlighted on The Heart.Organd showed superior efficacy for apixaban versus warfarin in stroke, systemic embolism, and all-cause death. The Heart.org also provided this nicely illustrated and definitive European Heart Rhythm Association guide to the use of the new oral anticoagulants, including edoxaban, the most recent direct anti-Xa inhibitor […]

read more

Comments (0)

Anticoagulant Therapy

May 9 2013

george

POCT ACT and Anti-Xa for ECMO

From Deanna Miller, Point of Care Testing (POCT) Coordinator at Children’s of Alabama: We have recently merged our extracorporeal membrane oxidation (ECMO) team with the cardiovascular team from the University of Alabama at Birmingham (UAB) and we are doing all pediatric cardiovascular cases at Children’s now. We would like some insight into monitoring coagulation using the activated coagulation time […]

read more

Comments (2)

Anticoagulant Therapy